业绩总结 - Bristol-Myers Squibb在心血管领域的关键目标是在心肌病和心力衰竭以及血栓形成方面持续关注CAMZYOS和milvexian[5] - Bristol-Myers Squibb在神经科学领域重新涉足，专注于建立多样化的药物组合，关注神经退行性疾病、神经炎症和神经肌肉疾病等领域[5] - Bristol-Myers Squibb在免疫学领域继续发展，特别关注风湿病领域的ORENCIA和肺部疾病领域的LPA-1拮抗剂[5] - Milvexian是Bristol-Myers Squibb在抗血栓领域的新方法，旨在提供比Eliquis更好的出血风险配置[8] - Milvexian的Phase 3研究已经在进行中，预计在2026年和2027年分别获得ACS和SSP以及AF的数据[8] - Milvexian的目标患者包括那些无法接受Factor Xa抑制剂的患者，如年长患者和患有肾脏疾病等的患者[10] - Bristol-Myers Squibb对Librexia AF的信心建立在Phase 2研究的数据基础上，计划在2026年获得ACS和SSP的数据，2027年获得AF的数据[12] - Bristol-Myers Squibb的DSMB定期监测所有三项研究的数据，以确保研究进展顺利[14] - Bristol-Myers Squibb对CAMZYOS和MYK-224在心力衰竭领域的研究充满信心，期待在2025年获得MYK-224的数据[18] - Bristol-Myers Squibb对KarXT在精神分裂症领域的Phase 3数据充满期待，预计在2025年获得数据[27] - KarXT在阿尔茨海默症精神病症状方面有潜力，xanomeline在患有可能患有阿尔茨海默症的患者中显示出益处[32] - M1通路对各种症状非常重要，可能与认知益处相关[34] - 公司对MTBR tau抗体项目充满信心，该项目有望在未来进行第二阶段研究[36] - 公司LP1拮抗剂在IPF和PPF的第三阶段研究中取得进展，显示出潜力[38]

Dividend Stocks That Could Deliver Life-Changing Returns relif / Getty Images 2022 was a dreadful year for investors, with the S&P 500 down almost 20% and the Nasdaq lower by a stunning 33%. What a difference a year can make. In 2023, the S&P 500 was up 24.2 %, with the longest weekly winning streak since 2004. The Nasdaq had an astounding 43.4% move higher, the most significant annual gain since 2020. The venerable Dow Jones Industrials came in up 13%.However, just ten companies have made up 95% of the g ...

In the latest trading session, Bristol Myers Squibb (BMY) closed at $50.89, marking a +0.28% move from the previous day. This change lagged the S&P 500's 0.8% gain on the day. Elsewhere, the Dow gained 0.23%, while the tech-heavy Nasdaq added 1.14%.The biopharmaceutical company's shares have seen an increase of 4.27% over the last month, surpassing the Medical sector's gain of 3.58% and falling behind the S&P 500's gain of 5.2%.Market participants will be closely following the financial results of Bristol M ...

Bristol Myers Squibb (BMY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this biopharmaceutical company have returned +4.2% over the past month versus the Zacks S&P 500 composite's +3.9% change. The Zacks Medical - Biomedical and Genetics industry, to which Bristol Myers belongs, has gained 2.3% over this period. Now the key question is: Where could the ...

NEW YORK--(BUSINESS WIRE)--Tapestry, Inc. (NYSE: TPR), a house of iconic accessories and lifestyle brands consisting of Coach, Kate Spade, and Stuart Weitzman, today announced that Kevin Hourican, President and Chief Executive Officer of Sysco Corporation (NYSE: SYY), and David Elkins, Executive Vice President and Chief Financial Officer of Bristol Myers Squibb (NYSE: BMY), have been appointed to the Company’s Board of Directors. The appointments of Mr. Hourican and Mr. Elkins to the Board bring the members ...

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update KIMMTRAK (tebentafusp) net revenues of $67.6 million in Q4 2023 and $238.7 million in 2023; increasing commercial access to KIMMTRAK globally, and pursuing future growth opportunities with two registrational trials in advanced cutaneous melanoma and adjuvant uveal melanoma Clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) with nivolumab in regi ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the TD Cowen 44th Annual Health Care Conference in Boston, Massachusetts, on Monday, March 4, 2024. Roland Chen, M.D., senior vice president, Immunology, Cardiovascular & Neuroscience development, will answer questions about the company during a fireside chat at 9:50 a.m. ET. Investors and the general public are invited to listen to a live webcast of the session here. An archived edition ...

收购详情 - 完成了对RayzeBio, Inc.的收购，RayzeBio现在是Bristol Myers Squibb的全资子公司[1] - Bristol Myers Squibb通过并购RayzeBio，加强了其肿瘤学管道，拓展了放射性药物治疗的新领域[2] - Bristol Myers Squibb以每股62.50美元的现金价格收购了RayzeBio的所有流通股份，总价约为41亿美元[3] 股东咨询 - RayzeBio的股东可以向信息代理Georgeson LLC咨询有关收购要约的问题[6] 顾问信息 - Bristol Myers Squibb的财务顾问是BofA Securities, Inc.，法律顾问是Covington & Burling LLP[7] 公司背景 - Bristol Myers Squibb是一家全球生物制药公司，致力于发现、开发和提供帮助患者战胜严重疾病的创新药物[8] 风险提示 - 本次收购存在一定的风险和不确定性，包括收购预期的好处未能实现、与收购协议相关的法律诉讼风险等[11]

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Blackstone Mortgage Trust, Inc. (BXMT) is a real estate finance company. The Zacks Consensus Estimate for its current year earnings has been revised 11.6% downward over the last 60 days.Bristol-Myers Squibb Company (BMY) is a biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 8.5% downward over the last 60 days.Clearway Energy, Inc. (CWEN) is a renewable energy company.The Zacks Cons ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that its previously announced tender offer (the “Offer”) to acquire all of the outstanding shares of RayzeBio, Inc. (Nasdaq: RYZB) common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion, expired at one minute after 11:59 p.m., Eastern Time, on February 22, 2024 (the “Expiration Time”). Equiniti Trust Company, the depositary for the Offer, has advised that, as of the Expiration Time, appr ...